Research
Hormonal
Sodium glucose cotransporter 2 inhibitors (SGLT2i) significantly reduce the composite risk of cardiovascular death or heart failure hospitalization in patients with heart failure with preserved ejection fraction (HFpEF), regardless of diabetes status.
If you have HFpEF, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs are proven to reduce the risk of heart failure hospitalization and cardiovascular death, even if you do not have diabetes. They are a standard part of modern treatment.
StrongSupportsHIGH confidence
The EMPEROR-Preserved trial randomized 5,988 HFpEF patients (with or without T2DM) 1:1 to empagliflozin or placebo... Compared with placebo, empagliflozin significantly reduced the composite endpoint risk of cardiovascular death or HF hospitalization.
Why this rating
Based on large-scale randomized controlled trials (EMPEROR-Preserved, DELIVER) with thousands of participants.
Source
Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies
Wenwen Zheng et al. · Diabetology & Metabolic Syndrome · 2025
DOI 10.1186/s13098-025-01917-z
narrative_reviewCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Once-weekly semaglutide (2.4 mg) significantly improves health-related quality of life and reduces body weight in obese patients with HFpEF.Good
- Exercise training (ET), including high-intensity interval training (HIIT) and moderate-intensity continuous training, improves functional status, exercise capacity, and quality of life in HFpEF patients.Good
- Lifestyle interventions, including dietary management (DASH/SDR, Low-Energy Diet) and exercise training, improve clinical outcomes in obese HFpEF patients.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →